|
May 2
|
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
|
|
May 2
|
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...
|
|
May 2
|
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
|
|
May 2
|
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
|
|
May 2
|
Regeneron Reports First Quarter 2024 Financial and Operating Results
|
|
May 1
|
Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
|
|
Apr 30
|
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
|
|
Apr 30
|
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
|
|
Apr 29
|
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
|
|
Apr 29
|
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
|
|
Apr 29
|
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
|
|
Apr 28
|
11 Oversold Growth Stocks to Buy Right Now
|
|
Apr 25
|
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma
|
|
Apr 25
|
Regeneron (REGN) Reports Next Week: What You Should Expect
|
|
Apr 25
|
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
|
|
Apr 25
|
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
|
|
Apr 25
|
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
|
|
Apr 25
|
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
|
|
Apr 25
|
Regeneron expands in gene editing with Mammoth deal
|
|
Apr 24
|
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
|